Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BCR-ABL1 compound mutations drive ponatinib resistance.

Cancer discovery - 1 Nov 2014

Abstract excerpt

BCR-ABL1 compound mutations harboring T315I are resistant to multiple TKIs, including ponatinib.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm
Share to Fusion Proteins, bcr-abl
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Pyridazines

Source

Identifiers

PMID: 25367954
DOI: 10.1158/2159-8290.CD-RW2014-186

Genes

ABL1
BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BCR-ABL1 compound mutations drive ponatinib resistance.PMID 25367954Read ↗

T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib.Semantic proximity Read ↗

Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.Semantic proximity Read ↗

BCR-ABL1 mutation ≠ ponatinib resistance.Semantic proximity Read ↗

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.Semantic proximity Read ↗

Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.Semantic proximity Read ↗

Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.Semantic proximity Read ↗

Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.Semantic proximity Read ↗

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaSemantic proximity Read ↗

Dynamic evolution of ponatinib-resistant mutations in BCR-ABL1-positive leukaemias revealed by next-generation sequencing.Semantic proximity Read ↗

Advances in Targeting BCR-ABLT315I Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules.Semantic proximity Read ↗

ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.Semantic proximity Read ↗

A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.